A study by researchers at Mass General Brigham hospital in Boston found that one in five COVID-infected individuals treated with antiviral ...

The National Institutes of Health (NIH) will conduct studies to test possible treatments for long COVID, a condition that affects millions ...

The challenge will be made harder by the arrival of the coronavirus's most infectious subvariant to date, XBB1.5. In the United States, whi...

Biden tested positive for COVID for the first time on July 21 and previously described his experience with the coronavirus as mild, saying ...

Biden's positive test is believed to be a "rebound" experienced by some COVID patients who take the anti-viral drug Paxlovid, according to ...

Several industry executives and doctors ET spoke to said at the moment, while cases are rising, the need for Paxlovid hasn't been felt as c...

"An Accord for a Healthier World" focuses on five areas: infectious diseases, cancer, inflammation, rare diseases and women's health -- whe...

The development of vaccines, notably in India, has benefited from funding by the Bill and Melinda Gates Foundation. In a new book, ' How to...

Authorities are fighting to curb the spread of the omicron variant among a population that lacks natural immunity and only has access to ho...

The variant could potentially slow the current decline of Covid cases.

The lab tests also showed that some antibodies have entirely lost their ability to neutralise Omicron at realistic dosages. "The bottom lin...

The Drug Controller General of India had last week approved Merck and Ridgeback’s antiviral molnupiravir for the treatment of mild-to-moder...

Experience with the Omicron variant so far makes clear that while vaccines are critical for reducing the virulence of the disease, therapie...

The Doha Declaration on TRIPS and public health clarified pre-existing flexibilities in the Agreement on Trade-Related Aspects of Intellect...